Dupont Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Dupont Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,012	Closed	-$290K	–	1439
2020 Q1	$290K	Buy	2,012 +276	+16%	+$53.3K	0.01%	875
2019 Q4	$355K	Sell	1,736 -1,786	-51%	-$326K	0.01%	1008
2019 Q3	$283K	Buy	+3,522	New	+$299K	0.01%	1021
2019 Q2	–	Sell	-4,350	Closed	-$372K	–	1286
2019 Q1	$372K	Buy	+4,350	New	+$361K	0.01%	869

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dupont Capital Management's RETA Position: Q2 2020 in Review

Dupont Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2020, closing a stake of 2,012 shares — an estimated $290K sold.

Dupont Capital Management first reported a position in RETA in Q1 2019 and held it in 4 quarters. The position peaked at $372K in Q1 2019. 207 funds tracked by Wall St. Rank hold RETA as of Q2 2020.

Dupont Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2020 after selling out during the quarter.
Dupont Capital Management sold 2,012 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2020, an estimated $290K.
Dupont Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 4 quarters.
Dupont Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $372K in Q1 2019.
207 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2020.

Based on Dupont Capital Management's 13F filing for Q2 2020, filed 24 Jul 2020.